International Prognostic Index - Age-Adjusted IPI

Age-Adjusted IPI

A simplified index can be used when comparing patients within an age group (i.e. 60 or younger, or over 60) and includes only 3 of the above factors:

• Stage
• LDH
• Performance status

The sum of the points allotted correlates with the following risk groups:

• Low risk (0 points) - 5-year survival of 83%
• Low-intermediate risk (1 point) - 5-year survival of 69%
• High-intermediate risk (2 points) - 5-year survival of 46%
• High risk (3 points) - 5-year survival of 32%

Although the IPI has shown itself to be a useful clinical tool, widely used by oncologists and a mainstay of risk stratification in clinical trials for lymphoma, it should be kept in mind that it was developed prior to the use of rituximab, which is now included with anthracycline-based combination chemotherapy as of the standard of care in B-cell lymphomas (the majority of non-Hodgkin's lymphomas). Rituximab has dramatically improved the outcomes of lymphoma patients, and its effect on the prognostic value of the IPI is uncertain.